Patent · US Active

Polymorphs

US10508123B2 · kind B2 · utility

0Cited by
0References
12Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 27, 2018
Grant dateDec 17, 2019
Priority date
Expiry dateAug 27, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to a polymorphic form of (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3-yl)-1H-imidazo[4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile and use as a therapeutic agent for the treatment of respiratory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.